Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Infectious Diseases and Therapy
Published in: Infectious Diseases and Therapy 2/2020

Open Access 01-06-2020 | Vaccination | Original Research

Estimating the Impact of Switching from a Lower to Higher Valent Pneumococcal Conjugate Vaccine in Colombia, Finland, and The Netherlands: A Cost-Effectiveness Analysis

Authors: Sarah Pugh, Matt Wasserman, Margaret Moffatt, Susana Marques, Juan Manuel Reyes, Victor A. Prieto, Davy Reijnders, Mark H. Rozenbaum, Juha Laine, Heidi Åhman, Raymond Farkouh

Published in: Infectious Diseases and Therapy | Issue 2/2020

Login to get access

Abstract

Introduction

Widespread use of ten-valent (Synflorix™, GSK) or 13-valent (Prevenar 13™; Pfizer) conjugate vaccination programs has effectively reduced invasive pneumococcal disease (IPD) globally. However, IPD caused by serotypes not contained within the respective vaccines continues to increase, notably serotypes 3, 6A, and 19A in countries using lower-valent vaccines. Our objective was to estimate the clinical and economic benefit of replacing PCV10 with PCV13 in Colombia, Finland, and The Netherlands.

Methods

Country-specific databases, supplemented with published and unpublished data, informed the historical incidence of pneumococcal disease as well as direct and indirect medical costs. A decision-analytic forecasting model was applied, and both costs and outcomes were discounted. The observed invasive pneumococcal disease (IPD) trends from each country were used to forecast the future number of IPD cases given a PCV13 or PCV10 program.

Results

Over a 5-year time horizon, a switch to a PCV13 program was estimated to reduce overall IPD among 0–2 year olds by an incremental − 37.6% in Colombia, − 32.9% in Finland, and − 26% in The Netherlands, respectively, over PCV10. Adults > 65 years experienced a comparable incremental decrease in overall IPD in Colombia (− 32.2%), Finland (− 15%), and The Netherlands (− 3.7%). Serotypes 3, 6A, and 19A drove the incremental decrease in disease for PCV13 over PCV10 in both age groups. A PCV13 program was dominant in Colombia and Finland and cost-effective in The Netherlands at 1 × GDP per capita (€34,054/QALY).

Conclusion

In Colombia, Finland, and The Netherlands, countries with diverse epidemiologic and population distributions, switching from a PCV10 to PCV13 program would significantly reduce the burden of IPD in all three countries in as few as 5 years.
Appendix
Available only for authorised users
Literature
1.
2.
Ardanuy C, Tubau F, Pallares R, Calatayud L, Dominguez MA, Rolo D, et al. Epidemiology of invasive pneumococcal disease among adult patients in Barcelona before and after pediatric seven-valent pneumococcal conjugate vaccine introduction, 1997–2007. Clin Infect Dis. 2009;48(1):57–64.PubMedCrossRef
3.
Berman M, Dube E, Quach C. Exploring the acceptability of the available pneumococcal conjugate vaccines in Canadian health care professionals and immunization experts. Vaccine. 2017;35(25):3326–32.PubMedCrossRef
4.
Bettinger JA, Scheifele DW, Kellner JD, Halperin SA, Vaudry W, Law B, et al. The effect of routine vaccination on invasive pneumococcal infections in Canadian children, Immunization Monitoring Program, Active 2000–2007. Vaccine. 2010;28(9):2130–6.PubMedCrossRef
5.
Casado-Flores J, Rodrigo C, Aristegui J, Martinon JM, Fenoll A, Mendez C. Decline in pneumococcal meningitis in Spain after introduction of the heptavalent pneumococcal conjugate vaccine. Pediatr Infect Dis J. 2008;27(11):1020–2.PubMedCrossRef
6.
Pilishvili T, Lexau C, Farley MM, Hadler J, Harrison LH, Bennett NM, et al. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis. 2010;201(1):32–41.PubMedCrossRef
7.
Rodenburg GD, de Greeff SC, Jansen AG, de Melker HE, Schouls LM, Hak E, et al. Effects of pneumococcal conjugate vaccine 2 years after its introduction, the Netherlands. Emerg Infect Dis. 2010;16(5):816–23.PubMedPubMedCentralCrossRef
8.
Ruckinger S, van der Linden M, Reinert RR, von Kries R, Burckhardt F, Siedler A. Reduction in the incidence of invasive pneumococcal disease after general vaccination with seven-valent pneumococcal conjugate vaccine in Germany. Vaccine. 2009;27(31):4136–41.PubMedCrossRef
9.
Vestrheim DF, Hoiby EA, Bergsaker MR, Ronning K, Aaberge IS, Caugant DA. Indirect effect of conjugate pneumococcal vaccination in a 2 + 1 dose schedule. Vaccine. 2010;28(10):2214–21.PubMedCrossRef
10.
Foster D, Walker AS, Paul J, Griffiths D, Knox K, Peto TE, et al. Reduction in invasive pneumococcal disease following implementation of the conjugate vaccine in the Oxfordshire region, England. J Med Microbiol. 2011;60(Pt 1):91–7.PubMedCrossRef
11.
Messina AF, Katz-Gaynor K, Barton T, Ahmad N, Ghaffar F, Rasko D, et al. Impact of the pneumococcal conjugate vaccine on serotype distribution and antimicrobial resistance of invasive Streptococcus pneumoniae isolates in Dallas, TX, children from 1999 through 2005. Pediatr Infect Dis J. 2007;26(6):461–7.PubMedCrossRef
12.
Munoz-Almagro C, Jordan I, Gene A, Latorre C, Garcia-Garcia JJ, Pallares R. Emergence of invasive pneumococcal disease caused by nonvaccine serotypes in the era of seven-valent conjugate vaccine. Clin Infect Dis. 2008;46(2):174–82.PubMedCrossRef
13.
Perez-Trallero E, Marimon JM, Ercibengoa M, Vicente D, Perez-Yarza EG. Invasive Streptococcus pneumoniae infections in children and older adults in the north of Spain before and after the introduction of the heptavalent pneumococcal conjugate vaccine. Eur J Clin Microbiol Infect Dis. 2009;28(7):731–8.PubMedCrossRef
14.
15.
Foster D, Knox K, Walker AS, Griffiths DT, Moore H, Haworth E, et al. Invasive pneumococcal disease: epidemiology in children and adults prior to implementation of the conjugate vaccine in the Oxfordshire region, England. J Med Microbiol. 2008;57(Pt 4):480–7.PubMedCrossRef
16.
Jokinen J, Rinta-Kokko H, Siira L, Palmu AA, Virtanen MJ, Nohynek H, et al. Impact of ten-valent pneumococcal conjugate vaccination on invasive pneumococcal disease in Finnish children—a population-based study. PLoS One. 2015;10(3):e0120290.PubMedPubMedCentralCrossRef
17.
Knol MJ, de Melker HE, Sanders EAM, van der Ende A, editors. Incidence of IPD in the Netherlands up to five years after introduction of PCV102016: National Institute for Public Health and the Environment.
18.
Brandileone MC, Almeida SCG, Minamisava R, Andrade AL. Distribution of invasive Streptococcus pneumoniae serotypes before and 5 years after the introduction of ten-valent pneumococcal conjugate vaccine in Brazil. Vaccine. 2018;36(19):2559–66.PubMedCrossRef
19.
RIVM Report. The National Immunisation Programme in the Netherlands. Surveillance and developments in 2016–2017. 2017.
20.
Isturiz R, Sings HL, Hilton B, Arguedas A, Reinert RR, Jodar L. Streptococcus pneumoniae serotype 19A: worldwide epidemiology. Expert Rev Vaccines. 2017;16(10):1007–27.PubMedCrossRef
21.
22.
Domenech M, Damian D, Ardanuy C, Linares J, Fenoll A, Garcia E. Emerging, non-PCV13 serotypes 11A and 35B of Streptococcus pneumoniae show high potential for biofilm formation in vitro. PLoS ONE. 2015;10(4):e0125636.PubMedPubMedCentralCrossRef
23.
Kawaguchiya M, Urushibara N, Aung MS, Morimoto S, Ito M, Kudo K, et al. Emerging non-PCV13 serotypes of noninvasive Streptococcus pneumoniae with macrolide resistance genes in northern Japan. New Microbes New Infect. 2016;9:66–72.PubMedCrossRef
24.
Su LH, Kuo AJ, Chia JH, Li HC, Wu TL, Feng Y, et al. Evolving pneumococcal serotypes and sequence types in relation to high antibiotic stress and conditional pneumococcal immunization. Sci Rep. 2015;5:15843.PubMedPubMedCentralCrossRef
25.
Wilson M, Wasserman M, Earnshaw S, McDade C, Pugh S, Moffatt M, Sings H, Hilton B, Farkouh R. Predicting invasive pneumococcal disease incidence: a forecasting approach. International Symposium on Pneumococcal and Pneumococcal Diseases. 2018.
26.
Wilson M, Wasserman M, Jadavi T, Postma M, Breton MC, Peloquin F, et al. Clinical and economic impact of a potential switch from 13-valent to 10-valent pneumococcal conjugate infant vaccination in Canada. Infect Dis Ther. 2018.
27.
Thorrington D, van Rossum L, Knol M, de Melker H, Rumke H, Hak E, et al. Impact and cost-effectiveness of different vaccination strategies to reduce the burden of pneumococcal disease among elderly in the Netherlands. PLoS One. 2018;13(2):e0192640.PubMedPubMedCentralCrossRef
28.
van Hoek AJ, Choi YH, Trotter C, Miller E, Jit M. The cost-effectiveness of a 13-valent pneumococcal conjugate vaccination for infants in England. Vaccine. 2012;30(50):7205–13.PubMedCrossRef
29.
Dagan R, Pelton S, Bakaletz L, Cohen R. Prevention of early episodes of otitis media by pneumococcal vaccines might reduce progression to complex disease. Lancet Infect Dis. 2016;16(4):480–92.PubMedCrossRef
30.
Tregnaghi MW, Saez-Llorens X, Lopez P, Abate H, Smith E, Posleman A, et al. Correction: efficacy of pneumococcal nontypable haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in young Latin American children: a double-blind randomized controlled trial. PLoS Med. 2015;12(6):e1001850.PubMedPubMedCentralCrossRef
31.
Ben-Shimol S, Givon-Lavi N, Leibovitz E, Raiz S, Greenberg D, Dagan R. Impact of widespread introduction of pneumococcal conjugate vaccines on pneumococcal and nonpneumococcal otitis media. Clin Infect Dis. 2016;63(5):611–8.PubMedCrossRef
32.
Macroeconomics and health: Investing in health for economic development. Report of the Commission on Macroeconomics and Health. Geneva: World Health Organization; 2001.
33.
34.
35.
Taboada BLL, Castro AL, Caicedo VMP, Camargo BCB, Roa BJH. Etiología de la neumonía adquirida en la comunidad en un hospital de cuarto nivel en Bogotá: estudio descriptivo de un registro institucional durante los años 2007 a 2012. Infection. 2015;19(1):10–7.CrossRef
36.
Constenla D, Gomez E, de la Hoz FP, O’Loughlin R, Sinha A, Valcnai JE, et al. The burden of pneumococcal disease and cost-effectiveness of a pneumococcal vaccine in Latin America and the Caribbean. Sabin Vaccine Inst. 2007;1:129.
37.
Castañeda-Orjuela, Carlos, Nelson Alvis-Guzmán, and Fernando De la Hoz-Restrepo. “Impacto de la enfermedad por Streptococcus pneumoniae en población adulta mayor en Bogotá, Colombia, 2008. Revista de Salud Pública 2010;12:38–50.
38.
National Institute for Health and Welfare. Incidence of invasive pneumococcal disease in Finland. 2016.
39.
Salo H. Economic evaluations in adopting new vaccines in the Finnish national vaccination programme. 2017.
40.
Vesikari T, Forsten A, Seppä I, Kaijalainen T, Puumalainen T, Soininen A, et al. Effectiveness of the 10-valent pneumococcal nontypeable haemophilus influenzae protein D-conjugated vaccine (PHiD-CV) against carriage and acute otitis media—a double-blind randomized clinical trial in Finland. J Pediatr Infect Dis Soc. 2016;5(3):237–48.CrossRef
41.
Palmu AA, Rinta-Kokko H, Nohynek H, Nuorti JP, Kilpi TM, Jokinen J. Impact of ten-valent pneumococcal conjugate vaccine on pneumonia in Finnish children in a nation-wide population-based study. PLoS One. 2017;12(3):e0172690.PubMedPubMedCentralCrossRef
42.
van Deursen AMM, Schurink-Van’t Klooster TM, Man WH, van de Kassteele J, van Gageldonk-Lafeber AB, Bruijning-Verhagen P, et al. Impact of infant pneumococcal conjugate vaccination on community acquired pneumonia hospitalization in all ages in the Netherlands. Vaccine. 2017;35(51):7107–13.PubMedCrossRef
43.
Eurostat. Hospital discharges by diagnosis, in-patients, per 100 000 inhabitants 2017 [Available from: http://​appsso.​eurostat.​ec.​europa.​eu/​nui/​show.​do?​query=​BOOKMARK_​DS-052702_​QID_​-5CE5B162_​UID_​-3F171EB0&​layout=​SEX,L,X,0;AGE,L,X,1;TIME,C,Y,0;GEO,L,Y,1;INDIC_​HE,L,Z,0;UNIT,C,Z,1;ICD10,L,Z,2;INDICATORS,C,Z,3;&​zSelection=​DS-052702UNIT,P_​HTHAB;DS-052702INDIC_​HE,INPAT;DS-052702ICD10,A-T_​Z;DS-052702INDICATORS​,OBS_​FLAG;&​rankName1=​ICD10_​1_​2_​-1_​2&​rankName2=​INDIC-HE_​1_​2_​-1_​2&​rankName3=​UNIT_​1_​2_​-1_​2&​rankName4=​INDICATORS_​1_​2_​-1_​2&​rankName5=​SEX_​1_​2_​0_​0&​rankName6=​AGE_​1_​2_​1_​0&​rankName7=​TIME_​1_​0_​0_​1&​rankName8=​GEO_​1_​2_​1_​1&​sortR=​ASC_​-1_​FIRST&​rStp=​&​cStp=​&​rDCh=​&​cDCh=​&​rDM=​true&​cDM=​true&​footnes=​false&​empty=​false&​wai=​false&​time_​mode=​ROLLING&​time_​most_​recent=​false&​lang=​EN&​cfo=​%23%23%23%2C%23%23%23.​%23%23%23.
44.
Koskela H. Keuhkokuumeen aiheuttama sairaalahoidon tarve nyt ja tulevaisuudessa. Suomen Lääkärilehti. 2013;18/2013, (vsk 68):1349–55.
45.
46.
Knol M, de Melker HE, Sanders EAM, van der Ende A, editors. Incidence of IPD in the Netherlands up to five years after introduction of PCV102016: National Institute for Public Health and the Environment.
47.
48.
van Vugt SF, Verheij TJ, de Jong PA, Butler CC, Hood K, Coenen S, et al. Diagnosing pneumonia in patients with acute cough: clinical judgment compared to chest radiography. Eur Respir J. 2013;42(4):1076–82.PubMedCrossRef
49.
Mangen MJ, Rozenbaum MH, Huijts SM, van Werkhoven CH, Postma DF, Atwood M, et al. Cost-effectiveness of adult pneumococcal conjugate vaccination in the Netherlands. Eur Respir J. 2015;46(5):1407–16.PubMedPubMedCentralCrossRef
50.
Wagenvoort GH, Sanders EA, Vlaminckx BJ, Elberse KE, de Melker HE, van der Ende A, et al. Invasive pneumococcal disease: clinical outcomes and patient characteristics 2–6 years after introduction of seven-valent pneumococcal conjugate vaccine compared to the pre-vaccine period, the Netherlands. Vaccine. 2016;34(8):1077–85.PubMedCrossRef
51.
Melegaro A, Edmunds WJ, Pebody R, Miller E, George R. The current burden of pneumococcal disease in England and Wales. J Infect. 2006;52(1):37–48.PubMedCrossRef
52.
Ordóñez JE, Orozco JJ. Cost-effectiveness analysis of the available pneumococcal conjugated vaccines for children under 5 years in Colombia. Cost Effect Resour Alloc. 2015;13(1):6.CrossRef
53.
Rozenbaum MH, Mangen MJ, Huijts SM, van der Werf TS, Postma MJ. Incidence, direct costs and duration of hospitalization of patients hospitalized with community acquired pneumonia: a nationwide retrospective claims database analysis. Vaccine. 2015;33(28):3193–9.PubMedCrossRef
54.
Rozenbaum MH, Sanders EA, van Hoek AJ, Jansen AG, van der Ende A, van den Dobbelsteen G, et al. Cost effectiveness of pneumococcal vaccination among Dutch infants: economic analysis of the seven valent pneumococcal conjugated vaccine and forecast for the ten valent and 13 valent vaccines. BMJ. 2010;340:c2509.PubMedCrossRef
55.
Bennett JE, Sumner W 2nd, Downs SM, Jaffe DM. Parents’ utilities for outcomes of occult bacteremia. Arch Pediatr Adolesc Med. 2000;154(1):43–8.PubMed
56.
Melegaro A, Edmunds WJ. Cost-effectiveness analysis of pneumococcal conjugate vaccination in England and Wales. Vaccine. 2004;22(31–32):4203–14.PubMedCrossRef
57.
Cheng AK, Niparko JK. Cost-utility of the cochlear implant in adults: a meta-analysis. Arch Otolaryngol Head Neck Surg. 1999;125(11):1214–8.PubMedCrossRef
58.
McIntyre PB, Berkey CS, King SM, Schaad UB, Kilpi T, Kanra GY, et al. Dexamethasone as adjunctive therapy in bacterial meningitis. A meta-analysis of randomized clinical trials since 1988. JAMA. 1997;278(11):925–31.PubMedCrossRef
59.
Pomeroy SL, Holmes SJ, Dodge PR, Feigin RD. Seizures and other neurologic sequelae of bacterial meningitis in children. N Engl J Med. 1990;323(24):1651–7.PubMedCrossRef
60.
Morrow A, De Wals P, Petit G, Guay M, Erickson LJ. The burden of pneumococcal disease in the Canadian population before routine use of the seven-valent pneumococcal conjugate vaccine. Can J Infect Dis Med Microbiol. 2007;18(2):121–7.PubMedPubMedCentralCrossRef
61.
62.
Mittmann N, Trakas K, Risebrough N, Liu BA. Utility scores for chronic conditions in a community-dwelling population. Pharmacoeconomics. 1999;15(4):369–76.PubMedCrossRef
63.
Stolk E, Krabbe P, Busschbach J, editor Using the internet to collect EQ-5D norm scores a valid alternative?. 24th Scientific Plenary Meeting of the EuroQol Group- Proceedings; 2009: EuroQol Group.
64.
Strutton DR, Farkouh RA, Earnshaw SR, Hwang S, Theidel U, Kontodimas S, et al. Cost-effectiveness of 13-valent pneumococcal conjugate vaccine: Germany, Greece, and The Netherlands. J Infect. 2012;64(1):54–67.PubMedCrossRef
65.
Klok RM, Lindkvist RM, Ekelund M, Farkouh RA, Strutton DR. Cost-effectiveness of a 10- versus 13-valent pneumococcal conjugate vaccine in Denmark and Sweden. Clin Ther. 2013;35(2):119–34.PubMedCrossRef
66.
Kulpeng W, Leelahavarong P, Rattanavipapong W, Sornsrivichai V, Baggett HC, Meeyai A, et al. Cost-utility analysis of 10- and 13-valent pneumococcal conjugate vaccines: protection at what price in the Thai context? Vaccine. 2013;31(26):2839–47.PubMedPubMedCentralCrossRef
67.
Kuhlmann A, von der Schulenburg JG. Modeling the cost-effectiveness of infant vaccination with pneumococcal conjugate vaccines in Germany. Eur J Health Econ. 2016.
68.
Lara C, De Graeve D, Franco F. Cost-effectiveness analysis of pneumococcal and influenza vaccines administered to children less than 5 years of age in a low-income District of Bogota, Colombia. alue Health Reg Issues. 2018;17:21–31.
69.
Shiragami M, Mizukami A, Leeuwenkamp O, Mrkvan T, Delgleize E, Kurono Y, et al. Cost-effectiveness evaluation of the ten-valent pneumococcal non-typeable haemophilus influenzae protein D conjugate vaccine and 13-valent pneumococcal vaccine in Japanese children. Infect Dis Ther. 2014.
70.
Delgleize E, Leeuwenkamp O, Theodorou E, Van de Velde N. Cost-effectiveness analysis of routine pneumococcal vaccination in the UK: a comparison of the PHiD-CV vaccine and the PCV-13 vaccine using a Markov model. BMJ Open. 2016;6(11):e010776.PubMedPubMedCentralCrossRef
71.
Wu DB, Chaiyakunapruk N, Chong HY, Beutels P. Choosing between 7-, 10- and 13-valent pneumococcal conjugate vaccines in childhood: a review of economic evaluations (2006–2014). Vaccine. 2015;33(14):1633–58.PubMedCrossRef
72.
Wasserman M, Sings HL, Jones D, Pugh S, Moffatt M, Farkouh R. Review of vaccine effectiveness assumptions used in economic evaluations of infant pneumococcal conjugate vaccine. Expert Rev Vaccines. 2018;17(1):71–8.PubMedCrossRef
73.
Limited IoESaR. Invasive Pneumococcal Disease in New Zealand, 2015. ESR. 2017.
74.
Desmet S, Verhaegen J, Van Ranst M, Peetermans W, Lagrou K. Switch in a childhood pneumococcal vaccination programme from PCV13 to PCV10: a defendable approach? Lancet Infect Dis. 2018.
75.
76.
Tagarro A, Benito A, Sanchez A, Aznar E, Otheo E, Sanz-Rosa D, et al. Bacteremic pneumonia before and after withdrawal of 13-valent pneumococcal conjugate vaccine from a public vaccination program in Spain: a case–control study. J Pediatr. 2016;171(111–5):e1–3.
77.
Picazo J, Ruiz-Contreras J, Mendez C, et al. Serotype distribution of invasive pneumococcal isolates among hospitalized children after systematic use of PCV7 in Madrid, Spain (HERACLES Study). ESPID 2008; Graz, Austria 2008.
Metadata
Title
Estimating the Impact of Switching from a Lower to Higher Valent Pneumococcal Conjugate Vaccine in Colombia, Finland, and The Netherlands: A Cost-Effectiveness Analysis
Authors
Sarah Pugh
Matt Wasserman
Margaret Moffatt
Susana Marques
Juan Manuel Reyes
Victor A. Prieto
Davy Reijnders
Mark H. Rozenbaum
Juha Laine
Heidi Åhman
Raymond Farkouh
Publication date
01-06-2020
Publisher
Springer Healthcare
Published in
Infectious Diseases and Therapy / Issue 2/2020
Print ISSN: 2193-8229
Electronic ISSN: 2193-6382
DOI
https://doi.org/10.1007/s40121-020-00287-5

Other articles of this Issue 2/2020

Infectious Diseases and Therapy 2/2020 Go to the issue

Original Research

Evaluation of the INCREMENT-CPE, Pitt Bacteremia and qPitt Scores in Patients with Carbapenem-Resistant Enterobacteriaceae Infections Treated with Ceftazidime–Avibactam

Letter

Letter to the Editor: Diagnostic Value of Virtual Bronchoscopic Navigation in the Bronchial Tuberculosis-Induced Central Airway Stenosis

Review

Carriage of Neisseria Meningitidis in Low and Middle Income Countries of the Americas and Asia: A Review of the Literature

Original Research

Reducing Blood Culture Contamination Rates: Experiences of Four Hospital Systems

Original Research

Health and Economic Impact of Routine Pediatric Pneumococcal Immunization Programs in Canada: A Retrospective Analysis

Original Research

Effectiveness of Elbasvir/Grazoprevir in US Veterans with Chronic Hepatitis C Virus Genotype 1b Infection
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits